36.26
price down icon1.01%   -0.37
after-market アフターアワーズ: 36.26
loading
前日終値:
$36.63
開ける:
$36.19
24時間の取引高:
552.06K
Relative Volume:
0.65
時価総額:
$3.50B
収益:
$225.27M
当期純損益:
$-140.06M
株価収益率:
-22.70
EPS:
-1.5974
ネットキャッシュフロー:
$-87.93M
1週間 パフォーマンス:
-5.62%
1か月 パフォーマンス:
-9.03%
6か月 パフォーマンス:
+17.31%
1年 パフォーマンス:
+34.70%
1日の値動き範囲:
Value
$36.00
$36.97
1週間の範囲:
Value
$36.00
$39.32
52週間の値動き範囲:
Value
$26.05
$42.68

Ideaya Biosciences Inc Stock (IDYA) Company Profile

Name
名前
Ideaya Biosciences Inc
Name
セクター
Healthcare (1060)
Name
電話
650-443-6209
Name
住所
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Name
職員
145
Name
Twitter
Name
次回の収益日
2026-11-03
Name
最新のSEC提出書
Name
IDYA's Discussions on Twitter

Compare IDYA vs VRTX, MRNA, REGN, ARGX, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
IDYA icon
IDYA
Ideaya Biosciences Inc
36.26 3.54B 225.27M -140.06M -87.93M -1.5974
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
505.64 127.93B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
196.48 79.40B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
742.12 81.13B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
928.44 60.03B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
200.87 43.93B 742.00K -1.37B -1.07B -7.0731

Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-07 再開されました UBS Buy
2025-11-24 開始されました Truist Buy
2025-09-18 開始されました Guggenheim Buy
2025-09-04 開始されました Barclays Overweight
2025-09-04 開始されました Citizens JMP Mkt Outperform
2025-07-22 開始されました TD Cowen Buy
2025-07-10 再開されました Goldman Neutral
2025-06-26 開始されました Wells Fargo Overweight
2024-11-18 開始されました Stephens Overweight
2024-11-05 ダウングレード Leerink Partners Outperform → Market Perform
2024-10-24 開始されました UBS Buy
2024-10-15 開始されました Cantor Fitzgerald Overweight
2024-07-08 開始されました Mizuho Outperform
2024-03-08 開始されました BTIG Research Buy
2023-08-08 開始されました SVB Securities Outperform
2023-05-24 開始されました Goldman Buy
2023-04-24 アップグレード Stifel Hold → Buy
2023-03-23 開始されました Berenberg Buy
2023-02-28 開始されました RBC Capital Mkts Outperform
2022-12-28 開始されました CapitalOne Overweight
2022-10-27 開始されました Citigroup Buy
2022-08-15 ダウングレード Stifel Buy → Hold
2022-07-18 再開されました Oppenheimer Outperform
2022-03-10 アップグレード Stifel Hold → Buy
2021-09-23 開始されました Stifel Hold
2021-06-04 再開されました Robert W. Baird Outperform
2021-03-11 開始されました Guggenheim Buy
2020-10-07 開始されました Wedbush Outperform
2020-09-01 開始されました Northland Capital Outperform
2020-07-13 アップグレード JP Morgan Neutral → Overweight
2020-06-17 繰り返されました H.C. Wainwright Buy
2020-04-06 開始されました H.C. Wainwright Buy
2020-03-13 開始されました ROTH Capital Buy
2019-10-17 開始されました Oppenheimer Outperform
2019-09-10 開始されました Robert W. Baird Outperform
2019-06-17 開始されました Citigroup Buy
2019-06-17 開始されました JP Morgan Neutral
2019-06-17 開始されました Jefferies Buy
すべてを表示

Ideaya Biosciences Inc (IDYA) 最新ニュース

pulisher
Sep 30, 2026

IDEAYA Biosciences stock reports Q2 revenue growth despite loss - AD HOC NEWS

Sep 30, 2026
pulisher
Sep 29, 2026

IDEAYA Biosciences, Inc. (IDYA) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 29, 2026
pulisher
Sep 28, 2026

IDEAYA Biosciences promotes Michael White to R&D president - Investing.com

Sep 28, 2026
pulisher
Sep 28, 2026

IDEAYA Biosciences promotes Dr. Michael White t... - Pluang

Sep 28, 2026
pulisher
Sep 28, 2026

Ideaya Biosciences Announces The Promotion Of Dr. Michael White To President, Research And Development - TradingView

Sep 28, 2026
pulisher
Sep 28, 2026

IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development - PR Newswire

Sep 28, 2026
pulisher
Sep 25, 2026

Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView

Sep 25, 2026
pulisher
Sep 25, 2026

Three new hires get options to buy 94,000 IDEAYA shares - Stock Titan

Sep 25, 2026
pulisher
Sep 25, 2026

Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold? - Yahoo Finance

Sep 25, 2026
pulisher
Sep 22, 2026

Cantor Fitzgerald reiterates Ideaya Biosciences stock rating By Investing.com - Investing.com Nigeria

Sep 22, 2026
pulisher
Sep 21, 2026

How (IDYA) Movements Inform Risk Allocation Models - Stock Traders Daily

Sep 21, 2026
pulisher
Sep 17, 2026

IDEAYA Biosciences stock gains attention as IDE-849 moves toward Phase 3 - AD HOC NEWS

Sep 17, 2026
pulisher
Sep 14, 2026

IDEAYA Biosciences at Morgan Stanley conference: darovasertib leads push By Investing.com - Investing.com Canada

Sep 14, 2026
pulisher
Sep 14, 2026

IDYA: Precision oncology pipeline advances with darovasertib, DLL3 ADC, and MTAP/KRAS programs - TradingView

Sep 14, 2026
pulisher
Sep 11, 2026

Citi Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65 - Moomoo

Sep 11, 2026
pulisher
Sep 10, 2026

IDEAYA at citigroup’s biopharma back to school summit 2026: pipeline breadth - Investing.com Canada

Sep 10, 2026
pulisher
Sep 10, 2026

IDYA: NDA submission, ESMO data, and Roche collaborations set the stage for major oncology advances - TradingView

Sep 10, 2026
pulisher
Sep 10, 2026

IDEAYA Biosciences at Cantor Fitzgerald conference: launch and pipeline push - Investing.com India

Sep 10, 2026
pulisher
Sep 09, 2026

IDEAYA Biosciences Doses First Patient in Phase 3 Trial - grafa.com

Sep 09, 2026
pulisher
Sep 09, 2026

Guggenheim raises Ideaya Biosciences stock price target on DLL3 data - Investing.com

Sep 09, 2026
pulisher
Sep 09, 2026

Guggenheim raises Ideaya Biosciences stock price target on DLL3 data By Investing.com - Investing.com Canada

Sep 09, 2026
pulisher
Sep 09, 2026

IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma - PR Newswire

Sep 09, 2026
pulisher
Sep 08, 2026

IDEAYA at wells fargo healthcare conference: darovasertib nears NDA By Investing.com - Investing.com Nigeria

Sep 08, 2026
pulisher
Sep 01, 2026

Phase III path opens for Ideaya’s IDE-849 in DLL3 ADC horse race - BioWorld News

Sep 01, 2026
pulisher
Sep 01, 2026

Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA) - theglobeandmail.com

Sep 01, 2026
pulisher
Sep 01, 2026

Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50 - Moomoo

Sep 01, 2026
pulisher
Sep 01, 2026

Citizens upgrades Ideaya Biosciences stock rating on IDE849 progress By Investing.com - Investing.com Nigeria

Sep 01, 2026
pulisher
Sep 01, 2026

IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences - 富途牛牛

Sep 01, 2026
pulisher
Sep 01, 2026

Citizens upgrades Ideaya Biosciences stock rating on IDE849 progress - Investing.com

Sep 01, 2026
pulisher
Sep 01, 2026

Avoiding Lag: Real-Time Signals in (IDYA) Movement - Stock Traders Daily

Sep 01, 2026
pulisher
Aug 31, 2026

IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer - PR Newswire

Aug 31, 2026
pulisher
Aug 31, 2026

IDEAYA Biosciences Plans Phase 3 Trial for Lung Cancer Therapy - Yahoo Finance

Aug 31, 2026
pulisher
Aug 28, 2026

IDEAYA Biosciences (IDYA) Slips 2.3% to $40.81 as Biotech Momentum FadesMomentum Factor - vinanet.vn

Aug 28, 2026
pulisher
Aug 28, 2026

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

Aug 28, 2026
pulisher
Aug 25, 2026

Ideaya Biosciences stock hits 52-week high at 40.88 USD By Investing.com - Investing.com Nigeria

Aug 25, 2026
pulisher
Aug 25, 2026

Ideaya Biosciences stock hits 52-week high at 40.88 USD - Investing.com

Aug 25, 2026
pulisher
Aug 25, 2026

Ideaya Biosciences: Darovasertib De-Risks A Self-Reinforcing Oncology Platform (IDYA) - Seeking Alpha

Aug 25, 2026
pulisher
Aug 23, 2026

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Eastern Progress

Aug 23, 2026
pulisher
Aug 23, 2026

IDEAYA (IDYA) Close: Adds 1.43% to Close at $39.67 at the Close; Technical Setup: the Near-Term Reference Band Stretches From $37.69 to $41.65 in the Available RecordOption Strike Build - careplusvn.com

Aug 23, 2026
pulisher
Aug 21, 2026

Great Lakes Advisors LLC Makes New Investment in IDEAYA Biosciences, Inc. $IDYA - MarketBeat

Aug 21, 2026
pulisher
Aug 19, 2026

IDEAYA (IDYA) Results Check: The EPS Result Is Below Expectation in Latest Trading; Shares Close 2.48% Higher for the Current SessionEarnings Miss Alert - Vinanet

Aug 19, 2026
pulisher
Aug 19, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 19, 2026
pulisher
Aug 19, 2026

IDEAYA partners with Genentech on pancreatic cancer trial By Investing.com - Investing.com South Africa

Aug 19, 2026
pulisher
Aug 19, 2026

IDEAYA partners with Genentech on pancreatic cancer trial - Investing.com

Aug 19, 2026
pulisher
Aug 19, 2026

IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer - PR Newswire

Aug 19, 2026
pulisher
Aug 16, 2026

Bank of America Corp DE Has $31.39 Million Stake in IDEAYA Biosciences, Inc. $IDYA - MarketBeat

Aug 16, 2026
pulisher
Aug 15, 2026

IDEAYA Biosciences (IDYA) Cash Flow Statement - Moomoo

Aug 15, 2026
pulisher
Aug 15, 2026

Walleye Capital LLC Buys Shares of 386,183 IDEAYA Biosciences, Inc. $IDYA - MarketBeat

Aug 15, 2026
pulisher
Aug 15, 2026

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Aug 15, 2026
pulisher
Aug 15, 2026

IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat

Aug 15, 2026
pulisher
Aug 14, 2026

Baker Bros. Advisors (IDYA) reports 5.2% IDEAYA stake and capped warrants - Stock Titan

Aug 14, 2026

Ideaya Biosciences Inc (IDYA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Ideaya Biosciences Inc (IDYA) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Ruiz Briseno Andres
Chief Accounting Officer
Jul 07 '26
Option Exercise
12.86
9,550
122,813
36,016
Ruiz Briseno Andres
Chief Accounting Officer
Jul 07 '26
Sale
40.01
9,550
382,131
26,466
$95.25
price down icon 0.50%
$34.75
price down icon 2.20%
$56.76
price up icon 0.57%
$224.41
price up icon 0.21%
ONC ONC
$364.02
price up icon 0.34%
$200.87
price up icon 0.50%
大文字化:     |  ボリューム (24 時間):